Advice
in the absence of a submission from the holder of the marketing authorisation:
pixantrone (Pixuvri®) is not recommended for use within NHS Scotland.
Indication under review: As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- pixantrone (Pixuvri)
- SMC ID:
- 1138/16
- Indication:
- As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas.
- Pharmaceutical company
- CTI Life Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 February 2016